CClinicalTrials.gg
CompletedNCT04115176GCFUpdated Oct 4, 2019

GCF IL-17 Levels and Oxidative Status of Smoking and Non-smoking Individuals With Periodontitis

An observational study in Chronic Periodontitis and Smoking, Cigarette, sponsored by Ondokuz Mayıs University. Completed at 1 site in Turkey. Open to participants aged 35 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Ondokuz Mayıs University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
35 Years to 60 Years
Sex
All
01

Study summary

This study was performed to evaluate the effects of both periodontal treatment and smoking on the gingival crevicular fluid(GCF) levels of interleukin (IL)-17A, IL-17E, Total oxidative stress(TOS) and total antioxidant capasity(TAOC) in smoking and non-smoking patients with severe chronic periodontitis.

Systemically healthy 15 smoker,15 non-smoker with chronic periodontitis were attended for the study. Periodontal status were determined by recording periodontal clinical measurements. GCF samples were collected at the baseline, at the end of initial periodontal treatment and 4 weeks after periodontal flap surgery. The data were tested statistically by the Student t and paired sample t tests.

02

Conditions studied

  • Chronic Periodontitis
  • Smoking, Cigarette

Keywords

  • chronic periodontitis
  • smoking,
  • periodontal treatment,
  • IL-17,
  • oxidative stress
03

In context

Periodontitis

1,634 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's enrollment of 30 is below the median of 89 across 427 observational studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Ondokuz Mayıs University is the lead sponsor of 262 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with chronic periodontitis (with an age range of 35 to 60 years) seeking dental treatment at the Periodontology Clinic, School of Dentistry, Ondokuz Mayis University, were included in the present study.

Inclusion criteria

  • individuals aged ˃35 years and having ≥16 teeth diagnosed as chronic periodontitis
  • not received any periodontal therapy within the previous 6 months;
  • not received antibiotic/anti-inflammatory drug treatment within the previous 6 months.

Exclusion criteria

Exclusion Criteria:

  • receiving medical treatment for cancer, rheumatoid arthritis, diabetes mellitus, cardiovascular disease, or any other systemic disease;
  • being pregnant or being in the period of menopause or lactation;
  • receiving any drug therapy that might affect the clinical characteristics of periodontitis;
  • usage of systemic antimicrobials during the 6 weeks prior to data collection
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • smokers + periodontitis

    Individuals clinically diagnosed with chronic periodontitis that smoke recruited for this group.

  • nonsmoker + periodontitis

    Individuals clinically diagnosed with chronic periodontitis that don't smoke recruited for this group.

06

What researchers measure

Primary outcomes

  1. GCF IL-17A VOLUME

    IL-17A is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.

    Time frame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .

  2. GCF IL-17E VOLUME

    IL-17E is a cytokine present in gingival crevicular fluid. Its volume calculated as microliter and changes due to inflammation caused by periodontal disease.

    Time frame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .

  3. GCF TOTAL OXIDATIVE STRESS (TOS) LEVEL

    TOS is the measurement of oxidative stress amount and given as mmol/L unit. Its amount changes due to inflammation caused by periodontal disease.

    Time frame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .

  4. GCF TOTAL ANTIOXIDANT CAPASITY (TAOC)

    TAOC is the antioxidant amount measured and given as μmol H2O2 Eq/L unit. Its amount changes due to inflammation caused by periodontal disease.

    Time frame: GCF sampling was performed prior to periodontal treatment , 4 weeks after completion of initial periodontal treatment, and 4 weeks after periodontal flap surgery .

07

Study locations

1 site
  • Müge Lütfioğlu
    Samsun, Atakum 55039, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04115176
Lead sponsor
Ondokuz Mayıs University
Responsible party
muge lutfioglu (Associate Professor, Ondokuz Mayıs University) — Principal investigator
First posted
Oct 3, 2019
Start date
Oct 10, 2017
Primary completion
Jul 10, 2019
Completion
Jul 10, 2019
Last update
Oct 4, 2019

Study contacts

MÜGE LÜTFİOĞLU
principal investigator · assoc. prof.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion